Vaccine Shedding: Facts, Myths, & More

A Mutation Story:

A gene known as HbS was the center of a medical and evolutionary detective story that began in the middle 1940s in Africa. Doctors noticed that patients who had sickle cell anemia, a serious hereditary blood disease, were more likely to survive malaria, a disease which kills some 1.2 million people every year. What was puzzling was why sickle cell anemia was so prevalent in some African populations.

How could a "bad" gene -- the mutation that causes the sometimes lethal sickle cell disease -- also be beneficial? On the other hand, if it didn't provide some survival advantage, why had the sickle gene persisted in such a high frequency in the populations that had it?

The sickle cell mutation is a like a typographical error in the DNA code of the gene that tells the body how to make a form of hemoglobin (Hb), the oxygen-carrying molecule in our blood. Every person has two copies of the hemoglobin gene. Usually, both genes make a normal hemoglobin protein. When someone inherits two mutant copies of the hemoglobin gene, the abnormal form of the hemoglobin protein causes the red blood cells to lose oxygen and warp into a sickle shape during periods of high activity. These sickled cells become stuck in small blood vessels, causing a "crisis" of pain, fever, swelling, and tissue damage that can lead to death. This is sickle cell anemia.

But it takes two copies of the mutant gene, one from each parent, to give someone the full-blown disease. Many people have just one copy, the other being normal. Those who carry the sickle cell trait do not suffer nearly as severely from the disease.

Researchers found that the sickle cell gene is especially prevalent in areas of Africa hard-hit by malaria. In some regions, as much as 40 percent of the population carries at least one HbS gene.

It turns out that, in these areas, HbS carriers have been naturally selected, because the trait confers some resistance to malaria. Their red blood cells, containing some abnormal hemoglobin, tend to sickle when they are infected by the malaria parasite. Those infected cells flow through the spleen, which culls them out because of their sickle shape -- and the parasite is eliminated along with them.

Scientists believe the sickle cell gene appeared and disappeared in the population several times, but became permanently established after a particularly vicious form of malaria jumped from animals to humans in Asia, the Middle East, and Africa.

In areas where the sickle cell gene is common, the immunity conferred has become a selective advantage. Unfortunately, it is also a disadvantage because the chances of being born with sickle cell anemia are relatively high.

For parents who each carry the sickle cell trait, the chance that their child will also have the trait -- and be immune to malaria -- is 50 percent. There is a 25 percent chance that the child will have neither sickle cell anemia nor the trait which enables immunity to malaria. Finally, the chances that their child will have two copies of the gene, and therefore sickle cell anemia, is also 25 percent. This situation is a stark example of genetic compromise, or an evolutionary "trade-off."

Sickle-Cell Anemia: A Look At Global Haplotype Distribution

Aidoo, M., et al. Protective effects of the sickle-cell gene against malaria morbidity and mortality. Lancet 359, 1311–1312 (2002)

Allison, A. C. The distribution of the sickle-cell trait in East Africa and elsewhere, and its apparent relationship to the incidence of subtertian malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene 48, 312–318 (1954)

——. Two lessons from the interface of genetics and medicine. Genetics 166, 1591–1599 (2004)

Centers for Disease Control and Prevention. Malaria. Centers for Disease Control and Prevention (2010)

Charache, S., et al. Effect of hydroxyurea on the frequency of painful crises in sickle-cell anemia. New England Journal of Medicine 332, 1317–1322 (1995)

Diggs, L. W., Ahmann, C. F., & Bibb, J. The incidence and significance of the sickle-cell trait. Annals of Internal Medicine 7, 769–778 (1933)

Hattori, Y., et al. Haplotypes of beta S chromosomes among patients with sickle-cell anemia from Georgia. Hemoglobin 10, 623–642 (1986)

Herrick, J. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Archives of Internal Medicine 6, 517–521 (1910)

Ingram, V. M. Gene mutations in human haemoglobin: The chemical difference between normal and sickle-cell haemoglobin. Nature 180, 326–328 (1957)

——. Abnormal human haemoglobins. III. The chemical difference between normal and sickle-cell haemoglobins. Biochimica et Biophysica Acta 36, 402–411 (1959)

Kan, Y. W., & Dozy, A. M. Antenatal diagnosis of sickle-cell anaemia by DNA analysis of amniotic-fluid cells. Lancet 2, 910–912 (1978a)

——. Polymorphism of DNA sequence adjacent to human beta-globin structural gene: Relationship to sickle mutation. Proceedings of the National Academy of Sciences 75, 5631–5635 (1978b)

——. Evolution of the hemoglobin S and C genes in world populations. Science 209, 388–391 (1980)

Kulozik, A. E., et al. Geographical survey of beta S-globin gene haplotypes: Evidence for an independent Asian origin of the sickle-cell mutation. American Journal of Human Genetics 39, 239–244 (1986)

Labie, D., et al. Common haplotype dependency of high G gamma-globin gene expression and high Hb F levels in beta-thalassemia and sickle-cell anemia patients. Proceedings of the National Academy of Sciences 82, 2111–2114 (1985)

Lapoumeroulie, C., et al. A novel sickle-cell mutation of yet another origin in Africa: The Cameroon type. Human Genetics 89, 333–337 (1992)

Lettre, G., et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle-cell disease. Proceedings of the National Academy of Sciences 105, 11869–11874 (2008)

Lux, S. E., John, K. M., & Karnovsky, M. J. Irreversible deformation of the spectrin-actin lattice in irreversibly sickled cells. Journal of Clinical Investigation 58, 955–963 (1976)

Marotta, C. A., et al. Human beta-globin messenger RNA. III. Nucleotide sequences derived from complementary DNA. Journal of Biological Chemistry 252, 5040–5053 (1977)

Miller, B. A., et al. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle-cell anemia. New England Journal of Medicine 316, 244–250 (1987)

Monteiro, C., et al. The frequency and origin of the sickle-cell mutation in the district of Coruche/Portugal. Human Genetics 82, 255–258 (1989)

Nagel, R. L., & Ranney, H. M. Genetic epidemiology of structural mutations of the beta-globin gene. Seminars in Hematology 27, 342–359 (1990)

Neel, J. V. The inheritance of sickle-cell anemia. Science 110, 64–66 (1949)

Oner, C., et al. Beta S haplotypes in various world populations. Human Genetics 89, 99–104 (1992)

Pagnier, J., et al. Evidence for the multicentric origin of the sickle-cell hemoglobin gene in Africa. Proceedings of the National Academy of Sciences 81, 1771–1773 (1984)

Pauling, L., et al. Sickle-cell anemia, a molecular disease. Science 110, 543–548 (1949)

Rahimi, Z., et al. Beta-globin gene cluster haplotypes in sickle-cell patients from southwest Iran. American Journal of Hematology 74, 156–160 (2003)

Rhinesmith, H. S., Schroeder, W. A., & Martin, N. The N-terminal sequence of the b chains of normal adult human hemoglobin. Journal of the American Chemical Society 80, 3358–3361 (1958)

Rhinesmith, H. S., Schroeder, W. A., & Pauling, L. A quantitative study of the hydrolysis of human dinitrophenyl (DNP) globin: The number and kind of polypeptide chains in normal adult human hemoglobin. Journal of the American Chemical Society 79, 4682–4686 (1957)

Rund, D., & Fucharoen, S. Genetic modifiers in hemoglobinopathies. Current Molecular Medicine 8, 600–608 (2008)

Schroeder, W. A., Munger, E. S., & Powars, D. R. Sickle-cell-anemia, genetic variations, and the slave-trade to the United States. Journal of African History 31, 163–180 (1990)

Sedgewick, A. E., et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells, Molecules, and Diseases 41, 255–258 (2008)

Steinberg, M. H. Predicting clinical severity in sickle-cell anaemia. British Journal of Haematology 129, 465–481 (2005)

——. SNPing away at sickle cell pathophysiology. Blood 111, 5420–5421 (2008)

Steinberg, M. H., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle-cell anemia: Risks and benefits up to nine years of treatment. Journal of the American Medical Association 289, 1645–1651 (2003)

Uda, M., et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proceedings of the National Academy of Sciences 105, 1620–1625 (2008)

---